Tel Aviv-based medtech company EyeControl is developing an AI-based, smart, screenless and wearable eye-tracking communication solution to reduce delirium, the company announced Monday.
Follow Israel Hayom on Facebook, Twitter, and Instagram
The company will display its new investigational device, EyeControl-Pro, at the American Delirium Society Conference (ADS), being held in Indianapolis from June 12-14.
Delirium is an acute mental disturbance characterized by confused thinking and disrupted attention sometimes accompanied by hallucinations. Delirium costs the US healthcare system up to $152 billion annually.
According to Or Retzkin, CEO of EyeControl, the company's goal is to "effectively empower the up to 80% of ICU patients experiencing delirium to communicate with their medical support team, family and friends, center and regain control of reality."
EyeControl will also share early data from its phase I clinical trial in Israel at Beilinson Hospital's ICU, where preliminary results include decreases in patient errors in the Confusion Assessment Method for the ICU (CAM-ICU), a validated Delirium screening tool, as well as improvements in Lowenstein Communication Scale (LCS) scores and patient engagement with hospital staff.
